证券代码：300110 证券简称：华仁药业 公告编号：2025-009 华仁药业股份有限公司 第八届监事会第六次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载，误导性陈述或重大遗漏。 一、监事会会议召开情况 华仁药业股份有限公司（以下简称"公司"）第八届监事会第六次会议于 2025 年 4 月 21 日以现场会议形式召开。会议通知已于 2025 年 4 月 10 日以电子邮件 方式发给各位监事。会议由监事会主席强力先生召集并主持，应出席会议的监事 3 名，实际出席会议的监事 3 名。会议召开符合法律法规、《公司法》及《公司章 程》的规定。 二、监事会会议审议情况 全体与会监事经认真审议和表决，形成以下决议： （一）审议通过《2024 年度监事会工作报告》 《2024 年度监事会工作报告》的具体内容详见公司同日披露在中国证监会指 定创业板信息披露网站巨潮资讯网的相关公告。 表决结果：赞成 3 票，反对 0 票，弃权 0 票，获得通过。 （四）审议通过《2024 年度利润分配预案》 监事会认为，本次利润分配预案符合《公司法》《公司章程》及相关法律法规 的要求，符合公司目前的 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载，误导性陈述或重大遗漏。 一、董事会会议召开情况 华仁药业股份有限公司（以下简称"公司"）第八届董事会第七次会议于 2025 年 4 月 21 日以现场和网络相结合形式召开。会议通知已于 2025 年 4 月 10 日以 电子邮件方式发给各位董事。会议由董事长杨效东先生召集并主持，应出席会议 的董事 8 名，实际出席会议的董事 8 名，全体监事及高级管理人员列席会议。会 议召开符合法律法规、《公司法》及《公司章程》的规定。 证券代码：300110 证券简称：华仁药业 公告编号：2025-008 华仁药业股份有限公司 第八届董事会第七次会议决议公告 董事会审议通过《2024 年度董事会工作报告》，认为公司第八届董事会切实 履行了《公司法》和《公司章程》所赋予的职责，认真贯彻落实了股东大会各项决 议，较好地完成了 2024 年各项工作任务。《2024 年度董事会工作报告》的具体内 容详见公司同日披露在中国证监会指定创业板信息披露网站巨潮资讯网的《2024 年年度报告》中"第三节 管理层讨论与分析"和"第四节 公司治理"等相关内容。 公司独立董 ...

证券代码：300110 证券简称：华仁药业 公告编号：2025-014 华仁药业股份有限公司 关于 2024 年度拟不进行利润分配的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载，误导性陈述或重大遗漏。 特别提示： 1、鉴于公司 2024 年度未实现盈利，且合并报表未分配利润为负，公司 2024 年度拟不派发现金红利，不送红股，不以公积金转增股本。 2、公司现金分红预案披露后，不触及《深圳证券交易所创业板股票上市规 则》第 9.4 条第（八）项规定的可能被实施其他风险警示情形。 一、审议程序 华仁药业股份有限公司（以下简称"公司"）于 2025 年 4 月 21 日召开第八届 董事会第七次会议和第八届监事会第六次会议，审议通过了《2024 年度利润分配 预案》，本议案尚需提交公司 2024 年度股东大会审议。 （一）董事会审议情况 公司 2024 年度利润分配预案为：鉴于公司 2024 年度未实现盈利，且合并报 表未分配利润为负，公司 2024 年度拟不派发现金红利，不送红股，不以公积金转 增股本。 （二）2024 年度拟不进行利润分配的原因 本次利润分配预案经公司第八届董事会 ...

华仁药业股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审核说明 中兴华会计师事务所(特殊普通合伙) ZHONGXINGHUA CERTIFIED PUBLIC ACCOUNTANTS LLP 地址：北京市丰台区丽泽路 20 号丽泽 SOHO Ｂ座 20 层 邮编：100073 电话：(010) 51423818 传真：(010) 51423816 目 录 一、专项说明 二、附表 中 兴 华 会 计 师 事 务 所 （ 特 殊 普 通 合 伙 ） Z H O N G X I N G H U A C E R T I F I E D P U B L I C A C C O U N T A N T S L L P 地 址 （ l o c a t i o n ）： 北 京 市 丰 台 区 丽 泽 路 2 0 号 丽 泽 S O H O B 座 2 0 层 20/F,Tower B,Lize SOHO,20 Lize Road,Fengtai District,Beijing PR China 电 话 （ t e l ）： 0 1 0 - 5 1 4 2 3 8 1 8 传 真 （ f a x ）： ...

华仁药业股份有限公司 2024年度营业收入扣除情况的 专项审核意见 中兴华会计师事务所(特殊普通合伙) ZHONGXINGHUA CERTIFIED PUBLIC ACCOUNTANTS LLP 地址：北京市丰台区丽泽路 20 号丽泽 SOHO Ｂ座 20 层 邮编：100073 电话：(010) 51423818 传真：(010) 51423816 关于华仁药业股份有限公司 营业收入扣除情况的专项审核意见 中兴华报字（2025）第 030095 号 华仁药业股份有限公司全体股东： 我们接受委托，在审计了华仁药业股份有限公司（以下简称"华仁药业"） 2024 年度财务报表的基础上，对后附的华仁药业按照《深圳证券交易所创业板 上市公司自律监管指南第 1 号——业务办理》的相关规定编制的《2024 年度营 业收入扣除情况表》（以下简称营业收入扣除情况表）进行了专项审核。 如实编制和对外披露营业收入扣除情况表，并确保其真实性、合法性及完整 性是华仁药业管理层的责任，我们的责任是在实施审核工作的基础上对营业收入 扣除情况表发表审核意见。 目 录 一、审核意见 二、审核意见附送 1. 营业收入扣除情况表 中 兴 华 会 ...

华仁药业股份有限公司 2024年度合并及母公司财务报表 审计报告书 中兴华会计师事务所(特殊普通合伙) ZHONGXINGHUA CERTIFIED PUBLIC ACCOUNTANTS LLP 地址：北京市丰台区丽泽路 20 号丽泽 SOHO B座 20 层 邮编：100073 电话：(010)51423818 传真：(010)51423816 目 录 三、审计报告附件 一、审计报告 二、审计报告附送 1. 合并资产负债表 2. 合并利润表 3. 合并现金流量表 4. 合并股东权益变动表 5. 母公司资产负债表 6. 母公司利润表 7. 母公司现金流量表 8. 母公司股东权益变动表 9. 财务报表附注 1. 中兴华会计师事务所（特殊普通合伙）营业执照复印件 2. 中兴华会计师事务所（特殊普通合伙）执业证书复印件 3. 注册会计师执业证书复印件 中 兴 华 会 计 师 事 务 所 （ 特 殊 普 通 合 伙 ） Z H O N G X I N G H U A C E R T I F I E D P U B L I C A C C O U N T A N T S L L P 地 址 （ lo c a t i o ...

华仁药业股份有限公司 内部控制审计报告书 中兴华会计师事务所(特殊普通合伙) ZHONGXINGHUA CERTIFIED PUBLIC ACCOUNTANTS LLP 地址：北京市丰台区丽泽路 20 号丽泽 SOHO Ｂ座 20 层 邮编：100073 电话：(010) 51423818 传真：(010) 51423816 中 兴 华 会 计 师 事 务 所 （ 特 殊 普 通 合 伙 ） Z H O N G X I N G H U A C E R T I F I E D P U B L I C A C C O U N T A N T S L L P 地 址 （ l o c a t i o n ）： 北 京 市 丰 台 区 丽 泽 路 2 0 号 丽 泽 S O H O B 座 2 0 层 20/F,Tower B,Lize SOHO,20 Lize Road,Fengtai District,Beijing PR China 电 话 （ t e l ）： 0 1 0 - 5 1 4 2 3 8 1 8 传 真 （ f a x ）： 0 1 0 - 5 1 4 2 3 8 1 6 内部控制审计报告 中兴华内 ...

Financial Performance - Revenue for Q1 2025 was CNY 303,472,326.57, a decrease of 25.38% compared to CNY 406,703,155.73 in the same period last year[2] - Net profit attributable to shareholders was CNY 16,028,449.64, down 68.46% from CNY 50,822,916.88 year-on-year[2] - Basic and diluted earnings per share were CNY 0.0136, a decline of 68.37% compared to CNY 0.0430 in the same period last year[2] - Total operating revenue decreased to ¥303,472,326.57 from ¥406,703,155.73, representing a decline of approximately 25.4% year-over-year[19] - Net profit for the period was ¥16,546,629.04, down from ¥52,378,184.34, reflecting a decline of approximately 68.4% year-over-year[20] - Operating profit decreased to ¥17,262,979.02 from ¥58,680,286.50, a drop of around 70.7% year-over-year[20] - The company reported a total comprehensive income of ¥16,546,629.04, down from ¥52,378,184.34, reflecting a decrease of about 68.4% year-over-year[20] Cash Flow and Investments - Net cash flow from operating activities decreased by 12.52% to CNY 96,675,551.41 from CNY 110,516,832.89 in the previous year[2] - The net cash flow from investment activities was negative CNY 25,822,417.54, a 114.37% increase in outflow compared to the previous year[9] - Cash flow from operating activities was ¥96,675,551.41, down from ¥110,516,832.89, a decrease of about 12.5% year-over-year[22] - The company incurred a net cash outflow from investing activities of ¥25,822,417.54, compared to a net outflow of ¥12,045,611.27 in the previous period[22] - The net cash outflow from financing activities was ¥54,282,863.33, an improvement from a net outflow of ¥221,122,266.65 in the previous period[23] Assets and Liabilities - Total assets increased by 0.64% to CNY 3,450,164,134.38 from CNY 3,428,120,079.39 at the end of the previous year[2] - As of March 31, 2025, the total assets of the company amounted to RMB 3,450,164,134.38, an increase from RMB 3,428,120,079.39 at the beginning of the period[17] - The total liabilities of the company were RMB 2,059,689,165.99, compared to RMB 2,054,191,740.04 at the beginning of the period, showing a slight increase of 0.27%[17] - The company's inventory decreased to RMB 281,481,226.88 from RMB 318,237,397.12, a decline of approximately 11.5%[16] - The company's long-term borrowings decreased to RMB 392,825,250.00 from RMB 464,080,000.00, a reduction of approximately 15.4%[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 43,490[10] - The total equity attributable to the parent company increased to RMB 1,316,814,738.65 from RMB 1,300,786,289.01, reflecting a growth of about 1.2%[18] Other Financial Metrics - The company reported a significant increase in accounts receivable by 189.58% to CNY 10,281,791.52 due to the receipt of certain bills[6] - The company experienced a 12,213.08% increase in other operating income, totaling CNY 2,118,208.88, primarily due to the write-off of long-term payables[8] - The company’s weighted average return on equity decreased to 1.22% from 1.87% year-on-year[2] - The company has fully provided for credit impairment losses on receivables from a subsidiary, indicating a cautious approach to financial management[13] - The company is in the process of executing a debt resolution framework with a partner, which remains uncertain and subject to further evaluation[14]

Financial Performance - The overall revenue of the company decreased compared to the previous year, resulting in a loss due to accounts receivable and goodwill impairment, as well as drug pricing policy impacts [4]. - The company’s financial report has been confirmed as true, accurate, and complete by its management team [4]. - The company’s operating revenue for 2024 was ¥1,353,161,818.05, a decrease of 17.30% compared to ¥1,636,256,356.79 in 2023 [24]. - The net profit attributable to shareholders for 2024 was -¥1,368,478,968.49, representing a decline of 827.67% from ¥188,063,014.38 in 2023 [24]. - The net cash flow from operating activities increased by 5.49% to ¥322,359,889.66 in 2024, compared to ¥305,597,473.45 in 2023 [24]. - The total assets at the end of 2024 were ¥3,428,120,079.39, down 33.64% from ¥5,165,697,057.91 at the end of 2023 [24]. - The net assets attributable to shareholders decreased by 51.72% to ¥1,300,786,289.01 at the end of 2024, compared to ¥2,694,091,730.12 at the end of 2023 [24]. - The basic earnings per share for 2024 was -¥1.1576, a decrease of 827.59% from ¥0.1591 in 2023 [24]. - The company reported a significant decline in the weighted average return on equity, which was -68.58% in 2024 compared to 7.20% in 2023 [24]. - The revenue after deducting non-recurring gains and losses for 2024 was ¥1,337,754,607.51, down from ¥1,540,143,589.53 in 2023 [25]. Operational Strategy - The company plans not to distribute cash dividends, issue bonus shares, or increase share capital from reserves [7]. - The report indicates that the company will focus on improving profitability through various measures, although specific strategies are not detailed in the provided content [4]. - The company maintains that its core business and competitive strengths have not undergone significant adverse changes, and there are no major risks to its ongoing operations [5]. - The company has detailed potential operational risks and corresponding countermeasures in the management discussion and analysis section of the report [5]. - The company emphasizes the support of national policies for pharmaceutical innovation, which is expected to foster industry growth [5]. - The company is actively responding to market changes and pressures, implementing a strategy of integrated development across raw materials, formulations, and packaging [58]. - The company aims to enhance its R&D capabilities by expanding product varieties and specifications, focusing on high-value, high-margin products, and integrating global advanced technology resources [99]. Market Environment - The pharmaceutical industry, where the company operates, is experiencing rapid changes and deep transformations, with a positive long-term outlook driven by aging population and increased health awareness [5]. - The pharmaceutical industry is undergoing rapid changes and transformations, presenting both challenges and new opportunities for the company in 2024 [35]. - The National Medical Insurance Bureau added 91 new drugs to the 2024 medical insurance catalog, significantly enhancing coverage for cancer, chronic diseases, rare diseases, and pediatric medications [36]. - The medical device market in China reached CNY 10,328 billion in 2023, with a five-year compound annual growth rate of approximately 14.67% [38]. - The pharmaceutical packaging industry in China is projected to grow from CNY 1,537 billion in 2023 to CNY 1,634 billion in 2024 [39]. Product Development and Innovation - The company has expanded its business from basic infusion and nephrology to respiratory and narcotic fields, diversifying its product forms to include various injection types, tablets, capsules, and granules [41]. - The company has enriched its R&D pipeline, focusing on high-value-added products in nephrology, respiratory, and therapeutic large-volume formulations, and was selected as a "2024 Qingdao City One Enterprise One Technology R&D Center" [59]. - The company has obtained 12 Class II medical device registration certificates and 3 Class I medical device filing certificates during the reporting period, totaling 35 Class II and 37 Class I medical devices [49]. - The company has made significant progress in expanding its product line, focusing on enhancing core competitiveness through new product registrations [80]. - The company has successfully completed the registration change for a disposable peritoneal dialysis drainage bag during the reporting period [83]. Compliance and Governance - The company emphasizes compliance and governance, integrating party leadership into its decision-making processes [104]. - The company has established a comprehensive procurement system to respect supplier rights and improve supply chain integration [173]. - The company has been recognized as a trustworthy unit for contract compliance for several consecutive years [173]. - The company is committed to maintaining good investor relations by regularly holding performance briefings and ensuring timely and accurate information disclosure [104]. - The company has established a framework to ensure that the compensation system is linked to the performance of the company’s return measures [183]. Environmental Responsibility - The company strictly adheres to various environmental protection laws and regulations, emphasizing sustainable development [161]. - The company has maintained effective internal controls over financial reporting as of December 31, 2024 [158]. - The company has established an emergency response plan for environmental incidents, which is regularly updated and filed with the ecological environment management department [164]. - The company has implemented a comprehensive waste management strategy, focusing on recycling and responsible waste disposal [168]. - The company reported that all monitored pollutants, including ammonia nitrogen and suspended solids, were within the regulatory limits [162]. Human Resources and Management - The total number of employees at the end of the reporting period was 2,491, with 538 in the parent company and 1,953 in major subsidiaries [146]. - The employee composition includes 1,557 production personnel, 265 sales personnel, and 483 technical personnel [147]. - The company has implemented a comprehensive training program to enhance employee skills and support long-term development [149]. - The company has established a performance-based compensation system to align employee incentives with business results [148]. - The company has a diverse board with members holding significant experience in finance and management [126]. Shareholder Relations - The company will hold a shareholders' meeting on May 16, 2024, to elect a new supervisor following the resignation of supervisor Jia Xuefei [124]. - The company has fully paid salaries to its directors, supervisors, and senior management during the reporting period [136]. - The company plans to distribute a cash dividend of RMB 0.21 per 10 shares to all shareholders, based on a total share capital of 1,182,212,982 shares as of December 31, 2023 [150]. - The company did not propose any cash dividend distribution for the 2024 fiscal year, despite having positive distributable profits [150]. - The company has committed to avoiding any competition with Huaren Pharmaceutical during its shareholding period [180].

华仁药业（300110）公告，2025年第一季度营业收入3.03亿元，同比下降25.38%。净利润1602.84万 元，同比下降68.46%。 ...